{"filings":[{"id":442973,"accession_number":"0001193125-26-224067","cik":1770069,"company_name":"MapLight Therapeutics, Inc.","ticker":"MPLT","form_type":"8-K","filed_at":"2026-05-14T20:15:32+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MapLight Therapeutics Q1 net loss $60.7M; completes enrollment in two Phase 2 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $60.7M in Q1 2026 vs $22.3M YoY; R&D expenses $53.7M, G&A $10.8M.","Cash and investments $395.2M as of March 31, 2026; expected to fund operations through 2027.","Enrollment completed in Phase 2 ZEPHYR trial (schizophrenia, n=307); topline data expected mid-August 2026.","Last patient visit completed in Phase 2 IRIS trial (autism, n=161); topline data also expected mid-August 2026.","Phase 2 VISTA trial for Alzheimer's disease psychosis ongoing; topline expected H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1239123088.5854483,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95316,"accession_number":"0001193125-26-191566","cik":1770069,"company_name":"MapLight Therapeutics, Inc.","ticker":"MPLT","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two MapLight directors not standing for reelection; Babler and Cox nominated","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D. will not stand for reelection at the June 23, 2026 Annual Meeting.","Board nominated Martin Babler and Troy Cox as Class I director nominees to replace them.","Both departures are not due to any disagreement with the Company on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1239123088.5854483,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108266,"accession_number":"0001193125-26-125062","cik":1770069,"company_name":"MapLight Therapeutics, Inc.","ticker":"MPLT","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MapLight Q4 net loss $79.5M; cash $453M; Phase 2 readouts expected Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $79.5M in Q4 2025 vs $21.2M year ago; FY2025 loss $161.2M vs $77.6M.","Cash, equivalents and investments $453.1M as of Dec 31, 2025, expected to fund operations through 2027.","Phase 2 ZEPHYR trial for schizophrenia: target enrollment (n=300) expected April 2026; topline results Q3 2026.","Phase 2 IRIS trial for autism spectrum disorder completed enrollment; topline results expected Q3 2026.","FDA Fast Track granted for ML-007C-MA in Alzheimer's disease psychosis; VISTA trial topline H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1239123088.5854483,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108265,"accession_number":"0001193125-26-008267","cik":1770069,"company_name":"MapLight Therapeutics, Inc.","ticker":"MPLT","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MapLight reports $450M cash; Phase 2 ZEPHYR & IRIS topline results now expected Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash and equivalents ~$450M as of Dec 31, 2025.","Phase 2 ZEPHYR trial for schizophrenia topline results expected Q3 2026; enrollment ahead of schedule.","Phase 2 IRIS trial for autism spectrum disorder completed enrollment; topline results also Q3 2026.","ZEPHYR is a 300-patient randomized double-blind placebo-controlled trial for acute psychosis.","IRIS trial randomized ~160 adult and adolescent participants with autism spectrum disorder."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1239123088.5854483,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124717,"accession_number":"0001193125-25-307450","cik":1770069,"company_name":"MapLight Therapeutics, Inc.","ticker":"MPLT","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MapLight reports Q3 net loss $29.4M; cash runway through 2027; Phase 2 readouts in 2026-2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.4M vs $19.0M in Q3 2024; R&D spend $27.1M (up 61% YoY) on clinical trial costs.","Cash & investments $227.2M at Q3 end; Oct IPO netted $269.8M, extending runway through 2027.","Phase 2 ZEPHYR (schizophrenia, n=300) topline H2 2026; VISTA (Alzheimer's psychosis) topline H2 2027.","ML-004 (autism) IRIS Phase 2 enrollment completed (~160 pts); topline results H2 2026.","ML-021 (Parkinson's) IND-enabling studies H2 2026; ML-009 (GPR52 PAM) candidate nominated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1239123088.5854483,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124716,"accession_number":"0001193125-25-255041","cik":1770069,"company_name":"MapLight Therapeutics, Inc.","ticker":"MPLT","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["3.02","8.01","5.03","9.01"],"status":"ready","headline":"MapLight Therapeutics prices IPO at $17/sh, raises $296.3M including concurrent private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 14.75M shares at $17.00; underwriters fully exercise option for 2.2125M additional shares.","Concurrent private placement to Goldman Sachs affiliates of 467,707 shares at same $17 price.","Total gross proceeds of $296.3M before underwriting discounts, placement agent fees, and expenses.","Amended and restated certificate of incorporation and bylaws effective upon IPO closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1239123088.5854483,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}